The efficacy of a commercial ELISA as an alternative to virus neutralisation test for the detection of antibodies to EAV.
Authors: Duthie S, Mills H, Burr P
Journal: Equine veterinary journal
Summary
# Editorial Summary: ELISA Validation for Equine Arteritis Virus Screening Equine arteritis virus (EAV) is a notifiable disease with significant breeding implications in the UK, particularly because stallions can become chronic carriers and transmit infection to mares. Although the virus neutralisation test remains the reference standard for serological screening prior to breeding, its labour-intensive nature and lengthy turnaround time have prompted investigation into faster alternatives. Duthie and colleagues evaluated a commercial ELISA kit against the gold-standard neutralisation test, finding that whilst the assay demonstrated excellent sensitivity (96%), its specificity was critically poor at only 26%—meaning it would generate an unacceptable number of false-positive results in a breeding screening context. This unacceptable specificity profile rendered the kit unsuitable for reducing sample processing time without compromising diagnostic accuracy. The findings underscore an important principle for equine practitioners and laboratories: commercial serological kits require rigorous in-house validation before implementation, particularly when results will inform breeding decisions or disease management protocols.
Read the full abstract on PubMed
Practical Takeaways
- •Do not rely solely on this commercial ELISA for EAV screening in breeding programmes; continue using virus neutralisation testing despite longer turnaround time
- •When evaluating new commercial diagnostic kits for any condition, validate them against your own samples before implementing in practice, as manufacturer claims may not reflect real-world performance
- •The poor specificity (26%) means this test would produce unacceptably high false-positive rates, leading to unnecessary restrictions on breeding stallions
Key Findings
- •Commercial ELISA for EAV antibody detection demonstrated poor specificity of 26% despite high sensitivity of 96%
- •Virus neutralisation test remains superior to ELISA for serological screening of EAV exposure in horses
- •Commercial diagnostic kits require in-house validation before clinical adoption to ensure reliability